AB Science S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABSCF research report →
Price Chart
About the company
AB Science S. A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors, designed for applications in both human and animal medicine.
- CEO
- Stéphane Ledermann
- IPO
- 2011
- Employees
- 36
- HQ
- Paris, IF, FR
Get TickerSpark's AI analysis on ABSCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $82.04M
- P/E
- -13.10
- PEG
- -0.18
- P/S
- 32.13
- P/B
- -2.19
- EV/EBITDA
- -32.97
- Div Yield
- 0.00%
- Gross Margin
- 61.33%
- Op Margin
- -103.66%
- Net Margin
- -132.62%
- ROE
- 6.99%
- ROIC
- -5.53%
Latest fiscal year · YoY change
- Revenue
- $1.17M+9.5%
- Gross Profit
- $719.73K-42.3%
- Op Income
- $-1,216,543
- Net Income
- $-1,556,416+80.1%
- EPS
- $-0.03+83.1%
- OCF Growth
- -916.6%
- FCF Growth
- -1334.9%
- 52W High
- $2.70
- 52W Low
- $1.12
- 50D MA
- $1.12
- 200D MA
- $1.26
- Beta
- 1.23
- RSI (14)
- 0
- Avg Volume
- 984
No earnings-call transcripts are available for ABSCF yet.
- Free Float
- 89.6%
- Shares Outstanding
- 73.25M
- Float Shares
- 65.63M
Our ABSCF coverage
Recent articles, reports, and earnings notes.
No research on ABSCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABSCF report →AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
globenewswire.com · Jun 9
AB Science : Stonegate Capital Partners updates its coverage of AB Science's stock with a target price of EUR 4.25 per share
globenewswire.com · Jun 2
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
globenewswire.com · May 25
AB Science reports its revenues for the year 2025 and provides an update on its activities
globenewswire.com · May 13
AB Science announces the successful completion of a EUR 3.2 million private placement
globenewswire.com · Apr 29
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
globenewswire.com · Apr 27
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
globenewswire.com · Apr 20
AB Science provides an update on its clinical development program.
globenewswire.com · Apr 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.